Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Wednesday, October 21, 2026
Disc Medicine’s $450 Million Public Offering
Arcus Biosciences’ $250 Million Public Offering
Arctic Therapeutics’ $21.5 Million Financing
Monday, October 19, 2026
Nouscom’s $135 Million Series D
Friday, October 16, 2026
Estuary’s $93 Million Series A
Microbiotica’s $48 Million Series C
Thursday, October 15, 2026
OrbiMed’s $3 Billion Fund Raise
OMass Therapeutics’ $310 Million Series C
Recursion’s $200 Million Public Offering
First Tracks Biotherapeutics’ $200 Million Private Placement
City Therapeutics’ $200 Million IPO
Acta Pharmaceuticals’ $24 Million Seed
Wednesday, October 14, 2026
Verastem Oncology’s $250 Million Public Offering
Altay Therapeutics’ $37 Million Series A
Vir Biotechnology’s $25 Million Private Placement
Tuesday, October 13, 2026
Alaunos Therapeutics’ $350 Million Private Placement
Thursday, October 8, 2026
Viatris’ $1.65 Billion Acquisition of Pacira BioSciences
ADC Therapeutics’ $87 Million Private Placement
Atrium Therapeutics’ $50 Million Private Placement
Retension Pharmaceuticals’ $45 Million IPO
Vinci Pharmaceuticals’ $8 Million Series A
Wednesday, October 7, 2026
TCGX’s $600 Million Fund Raise
Matchpoint Therapeutics’ $150 Million Series B
Tuesday, October 6, 2026
Forbion’s $2.6 Billion Fund Raise
Vaxcyte’s $500 Million Public Offering
KymaThera’s $80 Million Series B
RougeTx’s $58 Million Series A
Telomir’s $6 Million Private Placement
Monday, October 5, 2026
Shionogi’s $2.0 Billion Acquisition of IntraBio
Spyre’s $350 Million Public Offering
Consano Bio’s $15 Million Private Financing
Sunday, October 4, 2026
Thursday, October 1, 2026
Wednesday, September 30, 2026
Sagimet Biosciences’ $115 Million Public Offering
Pyxis Oncology’s $110 Million Public Offering
AnaCardio $70 Million Series B
Astrocyte’s $10 Million Series B
Tuesday, September 29, 2026
Immix Biopharma’s $125 Million Public Offering
Aptadir Therapeutics’ $45 Million Seed
Monday, September 28, 2026
Summit Therapeutics’ $2 Billion Private Placement
Link Cell Therapies’ $30 Million Series A Expansion
Thursday, September 24, 2026
Viking Therapeutics’ $275 Million Public Offering
Basecamp Research’s $140 Million Series C
United Immunity’s $11 Million Equity Financing
Celularity’s $10 Million Financing
HCW Biologics’ $1.5 Million Private Placement
Wednesday, September 23, 2026
Enveda’s $311 Million Series E
BigHat Biosciences’ $75 Million Series C
ViferaXS’s $13 Million Series A
Monday, September 21, 2026
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity is not a registered broker-dealer, and Finalis Securities LLC and Collabrity are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.
Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck | Finalis Form Customer Relationship Summary (“Form CRS”)
collabrityreport.com (the “Collabrity Report Website”) is a website operated by Collabrity. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Collabrity along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.